Cend Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cend Therapeutics, Inc.
AbbVie inks collaboration and option deal focused on targeted protein degradation with Plexium. Cend and Calabrius merge in an all-stock transaction.
The torpedoed IPO application of a Shanghai-based biotech has already triggered a ripple of unease among venture capitalists in China, with some signaling suspension of investment in similar ventures.
New regulatory measures shorten clinical trial approval times and usher in busy deal-making between large makers and smaller biotechs outside China.
Plus deals involving Scynexis/Hansoh, Cend/Qilu, Apollomics/Edison, Apollomics/Iterion, Apollomics/Nuance, Aerami/Chance, Antibe/Nuance, Ildong/Arbormed
- Drug Delivery
- Other Names / Subsidiaries
- DrugCendR Inc
- Impilo Therapeutics, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.